Skip to main content
. Author manuscript; available in PMC: 2022 Jul 1.
Published in final edited form as: Gait Posture. 2021 May 27;88:161–166. doi: 10.1016/j.gaitpost.2021.05.022

Table 3.

Comparison of gait performance.

Measures CIPN FoF+ CIPN FoF− Normal control P-value
(Group difference)
Gait speed (m/s) 0.78 ± 0.21 *,† 0.93 ± 0.17 ‡ 1.17 ± 0.13 P < .001
F(2,46) = 20.549
Stride length (meters) 0.99 ± 0.22 *,† 1.13 ± 0.15 1.26 ± 0.10 P < .001
F(2,46) = 10.699
Cadence (strides/min) 47.09 ± 7.06 * 49.47 ± 4.99 ‡ 56.00 ± 4.48 P < .001
F(2,46) = 10.840
Stride time (seconds) 1.31 ± 0.21 * 1.24 ± 0.12 ‡ 1.08 ± 0.09 P < .001
F(2,46) = 9.386

Note: Values are expressed as mean ± standard deviation.

*

Significant pairwise differences (p < .05) between the CIPN FoF+ and normal control groups.

†

Significant pairwise differences (p < .05) between the CIPN FoF+ and CIPN FoF− groups.

‡

Significant pairwise differences (p < .05) between the CIPN FoF− and normal control groups.

Abbreviations: CIPN = chemotherapy-induced peripheral neuropathy; FoF = fear of falling; m/s = meters/second, min = minutes.